“All three have enormous potential, but what is important for me, is that they validate the platform. We now have five commercial agreements against the background of the platform and more than 75 percent of the internal pipeline is based on the technology, so it is profoundly important for Genmab’s future.”
Those were the optimistic and, as per usual, slightly bombastic words from Genmab’s CEO, Jan van de Winkel, back in May when he told MedWatch about the biotech’s DuoBody platform and the partnerships it has struck for it.
Get full access for you and your coworkers.Start a free company trial today
Already a member? Log in.